Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1645 1648 1671
This examiner grants 66% of resolved cases
Rachel B. Gill works in Tech Center 1600 and Art Unit 1641, with 877 resolved cases. The allowance rate is 65.6%, and the median days to allowance is 912. These metrics show a solid success rate and an efficient timeline. The 65.6% rate is the primary benchmark for success, while the 912-day figure represents the typical duration for a grant. Practitioners can use these figures to set reliable expectations for applications in this art unit.
The interview lift is 28.3%, which is a significant increase over the 65.6% allowance rate. This 28.3% lift indicates that direct communication is highly beneficial with this examiner. With 877 resolved cases, the data suggests that oral advocacy is a key factor in successful outcomes. Practitioners should use the 912-day median and the 28.3% lift to optimize their strategy. These metrics provide a clear framework for achieving an allowance in Art Unit 1641.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18812841 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18796754 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | Non-Final OA | ModernaTX, Inc |
| 18030465 | DETECTION OF ACE2 IgM AUTOANTIBODIES AS MARKERS OF SEVERITY AND MECHANISM IN COVID19 PATIENTS | Non-Final OA | The Johns Hopkins University |
| 18701892 | DNA ORIGAMI SUBUNIT VACCINE FOR PREVENTION OF SARS-CoV-2 VARIANT INFECTION | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18701890 | HIGH SENSITIVITY DNA LINKED IMMUNOSORBENT SIGNAL AMPLIFICATION ASSAY (DLISA) FOR DETECTION OF INFECTIOUS SARS-COV-2 VIRUS AND VARIANTS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18786335 | METHODOLOGY TO CHARACTERIZE EMPTY-FULL RATIO IN CRUDE AAV SAMPLES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18712809 | IMMUNOGENIC COMPOSITIONS AND THEIR USES | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18712359 | VARICELLA-ZOSTER VIRUS IMMUNOGEN COMPOSITIONS AND THEIR USES | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 18699219 | PEPTIDE TARGETING FUSOBACTERIA, COMPOSITION FOR DIAGNOSING CANCER COMPRISING SAME, AND DRUG DELIVERY COMPOSITION | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18627824 | MULTIVALENT INFLUENZA VACCINES | Non-Final OA | SANOFI PASTEUR INC. |
| 17244333 | VIRAL TESTING IN SALIVA | Non-Final OA | The Regents of the University of Colorado |
| 18298540 | RAPID AND LOW-COST SAMPLING FOR DETECTION OF AIRBORNE SARS-COV-2 IN DEHUMIDIFIER CONDENSATE | Non-Final OA | University of Maryland, Baltimore |
| 18699034 | CORONAVIRUS VACCINES | Non-Final OA | Cambridge Enterprise Limited |
| 18579769 | METHOD OF TREATING DRUG RESISTANT ESKAPEE PATHOGENS USING THERAPEUTIC BACTERIOPHAGES | Non-Final OA | The Government of the United States, as Represented by the Secretary of the Army |
| 18684346 | NEXT GENERATION VACCINES COMPRISING ANTIGENIC LIBRARIES AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
| 18797069 | HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS | Non-Final OA | Salk Institute for Biological Studies |
| 18718766 | BACTERIOPHAGE LAMBDA-VACCINE SYSTEM | Non-Final OA | The U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18493133 | LASSA VIRUS VACCINE AND USES THEREOF | Non-Final OA | Inovio Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy